247 related articles for article (PubMed ID: 10483463)
1. Immunological factors which influence response to immunotherapy in malignant melanoma.
Morton D; Eilber FR; Malmgren RA; Wood WC
Surgery; 1970 Jul; 68(1):158-63; discussion 163-4. PubMed ID: 10483463
[TBL] [Abstract][Full Text] [Related]
2. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
Wile AG; Sparks FC; Morton DL
Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
[TBL] [Abstract][Full Text] [Related]
4. BCG immunotherapy in previously treated malignant melanoma patients.
Mujagić H; Kolarić K; Malenica B; Nola P
Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
[TBL] [Abstract][Full Text] [Related]
5. [Possibilities of immunotherapy in malignant melanoma].
Lewis MG
Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650
[TBL] [Abstract][Full Text] [Related]
6. HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients.
Buckley CE; White DH; Seigler HF
Monogr Allergy; 1977; 11():97-105. PubMed ID: 876133
[TBL] [Abstract][Full Text] [Related]
7. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in malignant melanomaa.
Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response.
Ahn SS; Irie RF; Weisenburger TH; Jones PC; Juillard G; Roe DJ; Morton DL
Surgery; 1982 Aug; 92(2):362-7. PubMed ID: 7101129
[TBL] [Abstract][Full Text] [Related]
10. Combined immunotherapy of malignant melanoma. Unusual survival following cerebral metastasis.
Spitler LE; Wong P; Sagebiel R
Arch Dermatol; 1978 Oct; 114(10):1501-4. PubMed ID: 718187
[TBL] [Abstract][Full Text] [Related]
11. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
12. Immune response and non-specific immunotherapy in melanoma.
El-Domeiri AA
Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
[TBL] [Abstract][Full Text] [Related]
13. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
14. [Basis for a specific-active immunotherapy in malignant melanoma].
Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
[TBL] [Abstract][Full Text] [Related]
15. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.
Lauerova L; Dusek L; Simickova M; Kocák I; Vagundová M; Zaloudík J; Kovarík J
Neoplasma; 2002; 49(3):159-66. PubMed ID: 12098001
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunological significance of human melanoma cytotoxic antibody.
Bodurtha AJ; Chee DO; Laucius JF; Mastrangelo MJ; Prehn RT
Cancer Res; 1975 Jan; 35(1):189-93. PubMed ID: 1109788
[TBL] [Abstract][Full Text] [Related]
17. Immunological monitoring of melanoma patients on BCG immunotherapy. I. Enzyme-linked immunosorbent assay of human sera after BCG-treatment.
Kovatchev D; Kolushky V; Engibarov A
Neoplasma; 1984; 31(4):453-8. PubMed ID: 6472516
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients.
Barrio MM; de Motta PT; Kaplan J; von Euw EM; Bravo AI; Chacón RD; Mordoh J
J Immunother; 2006; 29(4):444-54. PubMed ID: 16799340
[TBL] [Abstract][Full Text] [Related]
19. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
[TBL] [Abstract][Full Text] [Related]
20. Observations in immunotherapy of lymphoma and melanoma patients.
Thomas JW; Plenderleith IH; Clements DV; Landi S
Clin Exp Immunol; 1975 Jul; 21(1):82-96. PubMed ID: 1102163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]